| [1] |
WU Jialu, GE Xia, CHEN Wenming, YANG Guangzhong.
Current status and progress of CAR-T cell therapy in multiple myeloma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 525-531.
|
| [2] |
WANG Huijuan, CHEN Wenming, GENG Chuanying, YANG Guangzhong .
Clinical characteristics of patients with relapsed/refractory multiple myeloma after CAR-T cell therapy
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 549-553.
|
| [3] |
LI Yixue, LI Yajun, Zeng Ruolan, HE Yizi, WANG Caiqin, XIAO Ling, ZHOU Hui.
Current status of CAR-T therapy for multiple myeloma: Challenges and hopes coexist
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(4): 392-398.
|
| [4] |
XIAO Wanting, ZHANG Chunyan, TIAN Biao, GAO Yaya, GAO Guangxun.
A novel immunotherapy strategy for relapsed/refractory multiple myeloma: GPRC5D bispecific antibody
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(4): 399-404.
|
| [5] |
LIANG Yuanzheng, WANG Henan, WANG Liang.
Effects of PPP2R5C on proliferation, apoptosis, and drug sensitivity of multiple myeloma cells
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(4): 405-411.
|
| [6] |
ZHOU Da, WANG Mingyue, LI Zhe, HE Qing, CEN Hong.
Single-center clinical experience of daratumumab combined with bendamustine in the treatment of multiple myeloma patients with secondary extramedullary disease
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(4): 412-416.
|
| [7] |
IN Yuxuan, LIU Wei, YANG Hui, DING Cuiping.
Advances in the management of symptom clusters in patients with multiple myeloma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2023, 15(1): 98-103.
|
| [8] |
CHEN Xiaolei, ZHANG Yong, ZHANG Yue, LI Jie, ZHOU Hebing .
Retrospective analysis of efficacy and prognosis of newly diagnosed multiple myeloma patients with 1q21 amplification
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(5): 541-547.
|
| [9] |
WANG Jia, ZHAI Zhimin, GE Jian, WANG Xingbing, DONG Yi.
Effects of extramedullary diseases and regulatory T cells on the treatment efficacy of chimeric antigen receptor T cells in multiple myeloma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(4): 400-406.
|
| [10] |
LI Wanting, MA Liangming, LIAN Yu, WANG Quangang.
Research progress in patient?reported outcomes and multiple myeloma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(2): 229-233.
|
| [11] |
YANG Guangzhong, GENG Chuanying, WU Yin, LIU Aijun, LENG Yun, LI Yanchen, GAO Wen, CHEN Wenming.
Clinical efficacy of domestic bortezomib (Xintai) in the treatment of multiple myeloma and its safety
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(4): 385-388.
|
| [12] |
BAI Yinyin, XU Xinxin, LU Ling, GAN Huizhu.
Simultaneous multiple primary carcinomas with liver metastasis: a case report and literature review
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(1): 85-88.
|
| [13] |
GAO Peng, XIAO Zhongping, FU Kun, FENG Tao, YANG Dan, HAN Mei.
Expression of lncRNA MEG3 and lncRNA GAS5 in serum of multiple myeloma and its clinical significance
[J]. Chinese Journal of Oncology Prevention and Treatment, 2019, 11(4): 313-318.
|
